FDA's decision on Accelerated Approval for AP26113 will be based on the results from the past clinical and the on-going clinical data, and most importantly the voice/the need from doctors and cancer patients community. There is no difference whether completing the enrollment or the clinical trial itself.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.